ADPT
Adaptive Biotechnologies Corp
NASDAQ · Healthcare · Biotechnology · US
$28.61
+0.21%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.10
- Revenue estimate
- $71.6M
Latest reported
- Last report date
- Jul 29, 2026
- EPS actual
- -$0.25
- EPS estimate
- -$0.13
- Revenue actual
- $71.6M
- Revenue estimate
- $65.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -2.4%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $26
- PT range
- $22 – $28
- Analysts
- 6
5 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | -$0.13 | -$0.25 | Miss -87.11% | $71.6M |
| May 5, 2026 | -$0.16 | -$0.13 | Beat 18.75% | $70.9M |
| Feb 5, 2026 | -$0.19 | -$0.09 | Beat 52.63% | $71.7M |
| Nov 5, 2025 | -$0.16 | -$0.15 | Beat 6.25% | $94.0M |
| May 1, 2025 | -$0.28 | -$0.20 | Beat 28.57% | $52.4M |
| Nov 7, 2024 | -$0.30 | -$0.22 | Beat 26.67% | $46.4M |
| Aug 1, 2024 | -$0.32 | -$0.26 | Beat 18.75% | $43.2M |
| Feb 14, 2024 | -$0.32 | -$0.30 | Beat 6.25% | $45.8M |
| Nov 9, 2023 | -$0.32 | -$0.35 | Miss -9.37% | $37.9M |
| Aug 2, 2023 | -$0.33 | -$0.33 | In line | $48.9M |
| May 3, 2023 | -$0.34 | -$0.40 | Miss -17.65% | $37.6M |
| Feb 14, 2023 | -$0.37 | -$0.28 | Beat 24.32% | $55.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026